Levigress 750 Tablet contains Levetiracetam 750 mg, an antiepileptic medication indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in adults and pediatric patients. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Levigress 750 is typically prescribed as adjunctive therapy or monotherapy depending on the patient’s clinical profile. It demonstrates a favorable pharmacokinetic profile with rapid absorption, minimal protein binding, and predominant renal excretion, allowing for predictable dosing without significant drug interactions. Common adverse effects may include somnolence, dizziness, headache, and fatigue, while serious but rare side effects include behavioral changes, mood disturbances, and hypersensitivity reactions. Dose adjustment is recommended in patients with renal impairment to avoid toxicity. Levigress 750 should be used under strict medical supervision, with gradual dose titration to minimize adverse effects and optimize therapeutic outcomes. Regular monitoring of clinical response and side effects is essential to ensure efficacy and safety. Patients are advised not to discontinue therapy abruptly to prevent seizure exacerbation. This medication is contraindicated in individuals with known hypersensitivity to Levetiracetam or any excipients.